• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲萘醌对PTEN的抑制作用及对Akt的激活作用。

Inhibition of PTEN and activation of Akt by menadione.

作者信息

Yoshikawa Kyoko, Nigorikawa Kiyomi, Tsukamoto Mariko, Tamura Namiko, Hazeki Kaoru, Hazeki Osamu

机构信息

Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Minami-ku, Hiroshima 734-8553, Japan.

出版信息

Biochim Biophys Acta. 2007 Apr;1770(4):687-93. doi: 10.1016/j.bbagen.2006.12.009. Epub 2006 Dec 24.

DOI:10.1016/j.bbagen.2006.12.009
PMID:17276010
Abstract

Menadione (vitamin K(3)) has been shown to activate Erk in several cell lines. This effect has been shown to be due to the activation of EGF receptors (EGFR) as a result of inhibition of some protein tyrosine phosphatases. In the present study, we examined the effects of menadione on Akt in Chinese hamster ovary cells. The phosphorylation of Akt by menadione was not inhibited by AG1478, an inhibitor of EGFR. Menadione inhibited the lipid phosphatase activity of PTEN in a cell-free system. In an intact cell system, menadione inhibited the effect of transfected PTEN on Akt. Thus, one mechanism of its action was considered the accelerated activation of Akt through inhibition of PTEN. This was not the sole mechanism responsible for the EGFR-independent activation of Akt, because menadione attenuated the rate of Akt dephosphorylation even in PTEN-null PC3 cells. The decelerated inactivation of Akt, probably through inhibition of some tyrosine phosphatases, was considered another mechanism of its action.

摘要

甲萘醌(维生素K(3))已被证明能在多种细胞系中激活细胞外调节蛋白激酶(Erk)。这种效应已被证明是由于某些蛋白酪氨酸磷酸酶受到抑制,从而激活了表皮生长因子受体(EGFR)所致。在本研究中,我们检测了甲萘醌对中国仓鼠卵巢细胞中Akt的影响。甲萘醌对Akt的磷酸化作用不受EGFR抑制剂AG1478的抑制。甲萘醌在无细胞体系中抑制了第10号染色体缺失的磷酸酶及张力蛋白同源物(PTEN)的脂质磷酸酶活性。在完整细胞体系中,甲萘醌抑制了转染的PTEN对Akt的作用。因此,其作用机制之一被认为是通过抑制PTEN来加速Akt的激活。但这并非Akt非依赖EGFR激活的唯一机制,因为即使在PTEN基因敲除的PC3细胞中,甲萘醌也能减缓Akt的去磷酸化速率。Akt失活的减缓可能是通过抑制某些酪氨酸磷酸酶实现的,这被认为是其另一种作用机制。

相似文献

1
Inhibition of PTEN and activation of Akt by menadione.甲萘醌对PTEN的抑制作用及对Akt的激活作用。
Biochim Biophys Acta. 2007 Apr;1770(4):687-93. doi: 10.1016/j.bbagen.2006.12.009. Epub 2006 Dec 24.
2
Insulin attenuates the insulin-like growth factor-I (IGF-I)-Akt pathway, not IGF-I-extracellularly regulated kinase pathway, in luteinized granulosa cells with an increase in PTEN.胰岛素可减弱黄体化颗粒细胞中胰岛素样生长因子-I(IGF-I)-Akt信号通路,但不影响IGF-I-细胞外调节激酶信号通路,同时PTEN表达增加。
J Clin Endocrinol Metab. 2009 Jun;94(6):2184-91. doi: 10.1210/jc.2008-1948. Epub 2009 Mar 24.
3
Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.蛋白激酶抑制剂对 U87MG 脑胶质瘤细胞增殖抑制作用及其与表皮生长因子受体和磷酸酶张力蛋白基因表达的关系
Clin Exp Pharmacol Physiol. 2013 Jan;40(1):13-21. doi: 10.1111/1440-1681.12026.
4
Rat aortic smooth muscle cell density affects activation of MAP kinase and Akt by menadione and PDGF homodimer BB.大鼠主动脉平滑肌细胞密度影响甲萘醌和血小板衍生生长因子同型二聚体BB对丝裂原活化蛋白激酶(MAP激酶)和蛋白激酶B(Akt)的激活作用。
J Surg Res. 2001 Oct;100(2):197-204. doi: 10.1006/jsre.2001.6238.
5
PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.在KRAS野生型、激素难治性前列腺癌细胞中,PTEN表达通过介导PI3K/AKT和RAS/RAF/MAPK下游信号传导来控制细胞对西妥昔单抗的反应。
Oncol Rep. 2009 Mar;21(3):731-5.
6
PTEN-inhibition by zinc ions augments interleukin-2-mediated Akt phosphorylation.锌离子对PTEN的抑制作用增强了白细胞介素-2介导的Akt磷酸化。
Metallomics. 2014 Jul;6(7):1277-87. doi: 10.1039/c3mt00197k.
7
Critical role of PTEN in the coupling between PI3K/Akt and JNK1/2 signaling in ischemic brain injury.PTEN在缺血性脑损伤中PI3K/Akt与JNK1/2信号通路偶联中的关键作用。
FEBS Lett. 2007 Feb 6;581(3):495-505. doi: 10.1016/j.febslet.2006.12.055. Epub 2007 Jan 16.
8
A naphthoquinone derivative, shikonin, has insulin-like actions by inhibiting both phosphatase and tensin homolog deleted on chromosome 10 and tyrosine phosphatases.萘醌衍生物紫草素通过抑制10号染色体上缺失的磷酸酶和张力蛋白同源物以及酪氨酸磷酸酶而具有胰岛素样作用。
Mol Pharmacol. 2006 Sep;70(3):1143-9. doi: 10.1124/mol.106.025809. Epub 2006 Jun 27.
9
Loss of PTEN expression does not contribute to PDK-1 activity and PKC activation-loop phosphorylation in Jurkat leukaemic T cells.在Jurkat白血病T细胞中,PTEN表达缺失对PDK-1活性和PKC激活环磷酸化无影响。
Cell Signal. 2007 Dec;19(12):2444-57. doi: 10.1016/j.cellsig.2007.07.020. Epub 2007 Aug 3.
10
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.吉非替尼对PTEN阳性和PTEN阴性前列腺癌细胞系抗增殖和促凋亡作用的分子机制
Endocr Relat Cancer. 2005 Dec;12(4):983-98. doi: 10.1677/erc.1.00986.

引用本文的文献

1
Shikonin and Juglone Inhibit Low-Molecular-Weight Protein Tyrosine Phosphatase a (Mt-PTPa).紫草素和胡桃醌抑制低分子量蛋白酪氨酸磷酸酶a(Mt-PTPa)。
BioTech (Basel). 2023 Sep 20;12(3):59. doi: 10.3390/biotech12030059.
2
Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition.维生素K3甲萘醌的给药可改善因受体酪氨酸激酶抑制对角膜上皮伤口愈合产生的脱靶效应。
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):5864-5871. doi: 10.1167/iovs.16-19952.
3
Cell-type-specific roles of IGF-1R and EGFR in mediating Zn2+-induced ERK1/2 and PKB phosphorylation.
IGF-1R 和 EGFR 在介导 Zn2+-诱导的 ERK1/2 和 PKB 磷酸化中的细胞类型特异性作用。
J Biol Inorg Chem. 2010 Mar;15(3):399-407. doi: 10.1007/s00775-009-0612-7. Epub 2009 Nov 28.
4
Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis.维生素 K3(甲萘醌)抑制 Siah2 泛素连接酶可减弱低氧和 MAPK 信号通路并阻断黑素瘤的发生。
Pigment Cell Melanoma Res. 2009 Dec;22(6):799-808. doi: 10.1111/j.1755-148X.2009.00628.x. Epub 2009 Aug 27.
5
Rash from EGFR inhibitors: opportunities and challenges for palliation.表皮生长因子受体抑制剂引起的皮疹:姑息治疗的机遇与挑战
Curr Oncol Rep. 2008 Jul;10(4):304-8. doi: 10.1007/s11912-008-0048-1.